Picard Medical, Inc. · AMEX:PMI
Picard Medical — Investor Presentation (January 2026)
19 slides from Picard Medical's investor presentation, Jan 13, 2026
Slide 1: Investor Presentation: 1Q26
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Investor Presentation: 1Q26 NYSE: PMI
Slide 2: Forward-looking statements
This Presentation contains statements that are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward - looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by th
Slide 3: Our Mission
Our Mission To pioneer the future of heart replacement by providing the world’s first Total Artificial Heart and developing the next - generation system as an alternative to transplantation SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly o
Slide 4: SynCardia At-a-Glance
Market Leader: Global innovator in total artificial heart technology and a wholly owned subsidiary of Picard Medical, Inc. (NYSE American Ticker: PMI). Only FDA - Approved TAH: The SynCardia Total Artificial Heart (“STAH”) is the only commercially available total artificial heart approved by the FDA
Slide 5: Driving Scalable Growth with an Experienced, Results-Focused Team
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Driving Scalable Growth with an Experienced, Results - Focused Team CEO Patrick NJ Schnegelsberg COO Matt
Slide 6: Company Snapshot: Picard Medical
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Company Snapshot: Picard Medical (NYSE: PMI) (1) As of January 11, 2026 (2) August 29, 2025, to January 11
Slide 7: The Problem: Shortage of Donor Hearts Leaves Thousands Waiting
The Problem: Shortage of Donor Hearts Leaves Thousands Waiting SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Unmet Need: Significant Demand - Supply Imb
Slide 8: The Solution: The First FDA Approved Total Artificial Heart
The Solution: The First FDA Approved Total Artificial Heart — Designed for Hospital and Home Use SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Each pati
Slide 9: Years of Leadership: From First FDA Approval to Future Innovation
20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts FDA approves Companion C2 Driver FDA approves Freedom Driver FDA approves 50cc STAH US Patents covering fully implantable artificial hearts Patient Hospitalized Patient Mobile in Hospital
Slide 10: Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage
Text Text Text Text Text Text Text Text Text Text SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Clinically Validated: Peer - Reviewed Outcomes Demonstra
Slide 11: Utilized by High Volume Transplant Centers Across the U.S. and Europe
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Utilized by High Volume Transplant Centers Across the U.S. and Europe Centers of Excellence 1 High Volume
Slide 12: Lev'Veon's Story: Courage, Innovation, and a Lifesaving First
Sources: Mott Children’s Hospital & SynCardia Systems, LLC SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Lev’Veon’s Story: Courage, Innovation, and a Li
Slide 13: From Implant to Advocacy: Empowering Lives with the STAH
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. From Implant to Advocacy: Empowering Lives with the STAH Johnny Lemucchi, 55 years old Diagnosis: Congenit
Slide 14: Near-Term Growth Drivers: Site Expansion, Education, Access and Reimbursement
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Near - Term Growth Drivers: Site Expansion, Education, Enhancing Access and Reimbursement Protect existing
Slide 15: Mid-Term Growth Drivers: Label Expansion and Approvals
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Mid - Term Growth Drivers: Label Expansion and Approvals Set to Fuel U.S. and Global Commercial Momentum U
Slide 16: Long-Term Market Growth: Driven by R&D Pipeline and IP-Backed Innovation
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Long - Term Market Growth: Driven by R&D Pipeline and IP - Backed Innovation 2H28 1H28 2H27 1H27 2H26 1H26
Slide 17: Decades of Clinical Leadership in BTT Patients
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Decades of Clinical Leadership in BTT Patients: SynCardia’s Total Artificial Heart Outpaces Emerging Compe
Slide 18: Investment Drivers: Validated, Protected and Positioned for Growth
SynCardia's products are approved for sale in the U.S. and Canada only. SynCardia Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. Investment Drivers: Validated, Protected and Positioned for Growth Leader in High - Demand Market We belie
Slide 19: Delivering Proven Outcomes in the Toughest Cases
Addresses Most Severe Patients Delivering Proven Outcomes in the Toughest Cases SynCardia Total Artificial Heart (STAH) The STAH is approved for sale in the US and in Canada where it is indicated for use in cardiac transplant - eligible patients at risk of imminent death from biventricular failure.
Picard Medical — Investor Presentation (January 2026) on 6ix